DrugPatentWatch Database Preview
Drugs in Development Information for GKT137831
» See Plans and Pricing
What is the development status for investigational drug GKT137831?
GKT137831 is an investigational drug.
There have been 5 clinical trials for GKT137831.
The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2019.
The most common disease conditions in clinical trials are Fibrosis, Liver Cirrhosis, Biliary, and Cholangitis. The leading clinical trial sponsors are Genkyotex SA, University of Alabama at Birmingham, and York Bioanalytical Solution.
There are seven US patents protecting this investigational drug and sixty-two international patents.
Summary for GKT137831
| US Patents | 7 |
| International Patents | 62 |
| US Patent Applications | 9 |
| WIPO Patent Applications | 114 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2019-08-01) |
| Vendors | 63 |
Recent Clinical Trials for GKT137831
| Title | Sponsor | Phase |
|---|---|---|
| Study to Evaluate the Pharmacokinetics and Drug-Drug Interactions of Setanaxib in Healthy Adult Male and Female Subjects | Genkyotex SA | Phase 1 |
| GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis | University of Alabama at Birmingham | Phase 2 |
| Bioequivalence Study | Eurofins Optimed | Phase 1 |
Clinical Trial Summary for GKT137831
Top disease conditions for GKT137831
Top clinical trial sponsors for GKT137831
US Patents for GKT137831
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| GKT137831 | Start Trial | Skin enhancing compositions and methods | Sytheon Limited (Boonton, NJ) | Start Trial |
| GKT137831 | Start Trial | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (Plan-les-Ouates, CH) | Start Trial |
| GKT137831 | Start Trial | Methods of preserving and protecting pancreatic beta cells and treating or preventing diabetes by inhibiting NOX-1 | Eastern Virginia Medical School (Norfolk, VA) | Start Trial |
| GKT137831 | Start Trial | Orvepitant for chronic cough therapy | NeRRe Therapeutics Limited (Herts, GB) | Start Trial |
| GKT137831 | Start Trial | Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents | NeRRe Therapeutics Limited (Herts, GB) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for GKT137831
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| GKT137831 | European Patent Office | EP3532019 | 2036-10-31 | Start Trial |
| GKT137831 | South Korea | KR20190082254 | 2036-10-31 | Start Trial |
| GKT137831 | World Intellectual Property Organization (WIPO) | WO2018081779 | 2036-10-31 | Start Trial |
| GKT137831 | Australia | AU2009298008 | 2028-09-23 | Start Trial |
| GKT137831 | Brazil | BRPI0919330 | 2028-09-23 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
